New pharmaconutraceutical Chondroguard®TRIO for the prevention of musculoskeletal diseases and nutritional support for patients with osteoarthritis and nonspecific back pain: an assessment of clinical options. Resolution of the Multidisciplinary Expert Council
Authors:
Open Access
- 1 May 2023
- journal article
- research article
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 15 (2) , 134-146
Abstract
In recent decades, there has been an increase in the prevalence and medical and social burden of osteoarthritis (OA) and nonspecific back pain in all countries of the world. The First Multidisciplinary Bilateral Russia-Uzbekistan Expert Council presented innovations in the prognosing, personalized prevention and adjuvant therapy of degenerative-dystrophic diseases of the joints and spine, the evidence base for the effectiveness and safety of the use of drugs that modify the course of OA (Disease-modifying osteoarthritis drugs, DMOADs): chondroitin sulfate, glucosamine sulfate, undenatured type II collagen for adjuvant pharmaconutraceutical support – prevention and adjuvant therapy (treatment) of OA and nonspecific lumbosacral pain. The expert counsil resolution presents an optimized algorithm for the management, prevention and adjuvant therapy of OA and non-specific back pain, maintaining the function of healthy joints after intense physical activity with the inclusion of the drug Chondroguard solution for intra-articular and intramuscular administration (INN – chondroitin sulfate) and a new pharmaconutraceutical from the DMOADs group – TRIO trademark Chondroguard® (Chondroguard®TRIO).Keywords
This publication has 58 references indexed in Scilit:
- Crystalline glucosamine sulfate in the management of knee osteoarthritis: efficacy, safety, and pharmacokinetic propertiesTherapeutic Advances in Musculoskeletal Disease, 2012
- Osteoarthritis: A disease of the joint as an organArthritis & Rheumatism, 2012
- Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysisBMJ, 2010
- Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE systemBMC Musculoskeletal Disorders, 2008
- IL-10 overexpression differentially affects cartilage matrix gene expression in response to TNF-α in human articular chondrocytes in vitroCytokine, 2008
- Biochemical basis of the effect of chondroitin sulphate on osteoarthritis articular tissuesAnnals of the Rheumatic Diseases, 2008
- Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science studyArthritis Research & Therapy, 2007
- Glucosamine therapy for treating osteoarthritisCochrane Database of Systematic Reviews, 2005
- Biochemical injection treatment for discogenic low back painThe Spine Journal, 2003
- Physical exercise as a human model of limited inflammatory responseCanadian Journal of Physiology and Pharmacology, 1998